News
Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...
Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.
Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...
Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...
TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...
Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...
By Rachel Cohrs Zhang, Derek Wallbank, and Hadriana Lowenkron President Donald Trump said he plans to order a cut in US ...
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...
Nine days later, the same four retailers sued Israel’s Teva Pharmaceuticals ... lawsuit. Takeda sued to stop competition from generic manufacturers, including TWi, and those two companies ...
Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback